since 2008, evaxion biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence, with the mission to solve some of the world’s most significant challenges to human health. evaxion has constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, pioneer and eden. using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. eden enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while pioneer has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them. to learn more about evaxion, please visit http://www.evaxion-biotech.ai
Company profile
Ticker
EVAX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
EVAX stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
17 Apr 24
6-K
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
2 Apr 24
6-K
Notice of Annual General Meeting
29 Mar 24
6-K
Evaxion Announces Business Update and Full Year 2023 Financial Results
27 Mar 24
20-F
2023 FY
Annual report (foreign)
26 Mar 24
6-K
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
19 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
20 Feb 24
6-K
Current report (foreign)
7 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
2.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 106.70 mm |
Total shares | 122.71 k |
Total puts | 0.00 |
Total calls | 11.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AE Wealth Management | 48.63 k | $40.51 mm |
Susquehanna International | 32.77 k | $28.19 mm |
Two Sigma Securities | 15.19 k | $12.65 mm |
JPM JPMorgan Chase & Co. | 9.28 k | $7.98 mm |
Beacon Capital Management | 6.88 k | $9.01 mm |
UBS UBS Group AG - Registered Shares | 4.01 k | $3.34 mm |
MS Morgan Stanley | 3.45 k | $2.87 mm |
Rhumbline Advisers | 2.11 k | $1.81 mm |
Group One Trading | 386.00 | $332.00 k |
Proequities | 0.00 | $0.00 |
News
HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
3 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
2 Apr 24
Ladenburg Thalmann Upgrades Evaxion Biotech to Buy, Announces $8 Price Target
2 Apr 24
Recap: Evaxion Biotech Q4 Earnings
27 Mar 24
Evaxion Biotech Q4 EPS $(0.16) Beats $(1.60) Estimate, Sales $73.00K
27 Mar 24
Press releases
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
17 Apr 24
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
2 Apr 24
Evaxion Announces Business Update and Full Year 2023 Financial Results
27 Mar 24
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
19 Mar 24
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
29 Feb 24